A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C

BACKGROUND: The recommended treatment for patients infected with hepatitis C virus genotype 2 (HCV2) is pegylated interferon (peginterferon) and ribavirin for 24 weeks. AIM: To assess whether a shorter 16‐week treatment is as effective as a standard 24‐week treatment. METHODS: Patients with HCV2 inf...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Yu, Ming‐Lung, Dai, Chia‐Yen, Huang, Jee‐Fu, Hou, Nai‐Jen, Lee, Li‐Po, Hsieh, Ming‐Yen, Chiu, Chang‐Fu, Lin, Zu‐Yau, Chen, Shinn‐Cherng, Hsieh, Ming‐Yuh, Wang, Liang‐Yen, Chang, Wen‐Yu
Materialtyp: Artigo
Språk:Inglês
Publicerad: BMJ Group 2007
Ämnen:
Hepatitis
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC1856839/
https://ncbi.nlm.nih.gov/pubmed/16956917
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gut.2006.102558
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk